Genmab — Januar 2021
-
-
Genmab og Seattle Genetics arbejder på at søge om en accelereret godkendelse i USA baseret på fase-2 data. Midlet kan så eventuelt blive tilgængeligt for patienterne i andet halvår 2021.
-
-
Transactions with shares and linked securities in Genmab A/S m https://ml-eu.globenewswire.com/Resource/Download/d65dc065-2051-4cf7-99be-c97fbb4acd7b
ade by managerial employees and their closely associated persons -
-
God morgen.
-
Så var der vist ny ATH
-
Mogan - jeg vil være tilfreds med +20% i 2021. 2020 var et ekstraordinært år, som nok ikke lige så let gentager sig...
-
Jan er god til at opbygge forventninger. Og der allerede meget høje forventninger til Epcoritamab og gen1046. Det skal skal så også fastslås at Genmab er dygtige til at leve op til høje forventninger...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind